AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications
This article was originally published in The Pink Sheet Daily
Executive Summary
An updated analysis showing no overall survival advantage for vandetanib, plus feedback from both FDA and EMEA that progression-free survival was not enough, caused AstraZeneca to withdraw the filings.